According to Fortune, Globelmmune has pulled the plug on its IPO, citing market conditions for the reason. The publication reported that the company had planned to offer 5 million shares at between $11 and $13 per share. Wells Fargo and Jefferies were the lead underwriters. Based in Louisville, Colorado, Globelmmune is a biopharmaceutical company that develops therapeutic vaccines to treat cancer and infectious diseases. Its investors include Celgene International, HealthCare Ventures, Morgenthaler Ventures, Wexford Capital, Sequel Ventures, Lilly Ventures and Medica Venture Partners.